History is full of examples of how generative value can be created in moments of crisis; and Covid-19 has been no different. Did you know that the Japanese understanding of ‘crisis’ (危機) encompasses both “danger” (危) and “opportunity” (機), implying that even in the most adverse of circumstances there can arise creations of genius and beacons of hope? Indeed, we have witnessed many examples of accelerated innovation processes during the Covid-19 pandemic. Yes, whilst the pandemic has been raging, we have seen efficient and effective product development from both ground-zero starting positions and from clever adaptation of existing products. A true example of such innovation providing a beacon of hope came to Lan’s attention in Spring 2020, shortly after the pandemic was taking hold. Lan was introduced to a portfolio of new breakthrough products that had been developed by scientists at Korean-based ‘CLOBIO’ lab to specifically address the health crisis brought by SARS-CoV-2 (COVID-19). Each product is based on patent-pending technology that regulates and distributes the slow re- lease of low concentration (below 0.1ppm) Chlorine Dioxide (ClO2) to dissolve 99.9% of the SARS-CoV-2 (COVID-19) and over 600 other viruses and bacteria. Studies have shown that the virus is eradicated in less than 10 seconds, which is the time it takes for the ClO2 gas to reach the virus. Once there is contact, the disintegration is almost instant. The concentration of ClO2 in all products is approved for humans and the environment according to studies by the World Health Organisation (WHO) and the FDA. ClO2, in the correct concentra- tion, is also safely used as a disinfectant for water and in other industries (such as household, medical, and food). The CLOBIO founders, Kiho Ri and JinYoung Park, were responsible for discovering the now globally-recognised characteristic of Chlorine Dioxide (ClO2) as an agent to maintain the fresh- ness of produce, potentially disrupting the market incumbent, a silica gel preservative. In 2018, they turned their research to antiviral medicines after the repetitive emergence of highly pathogenic viruses. By 2020, when the Coronavirus became a global pandemic, CLOBIO had already developed many types of fundamental materials based on Chlorine Dioxide. Tests in Korea on ClO2 (in terms of toxicity, skin etc) proved that there are no side effects. Staggered at the science behind the business, Lan quickly saw a fantastic opportunity to support a company that could make huge waves in helping the world to combat this new virus. So she established Swiss-based ‘V+Guard AG’, a brand that holds the worldwide exclusive 10-year distribution agreement for all products developed and produced by CLOBIO.